Research on Parkinson's disease and its treatment. Covers mitochondrial protection, genetic progression markers, antibody therapies, and disease costs.
The article reviews lessons learned from Alzheimer's disease research to advance the development of screening and diagnostic algorithms for Parkinson's disease. It explores MCI-AD research, clinical trials incorporating biomarkers and genetics, and emerging therapeutic strategies targeting specific biological mechanisms.
Research reveals individual corals have varying capacities to adapt to changing ocean conditions brought about by climate change. The study found that some corals are more protective of their partner algae in harsh environmental conditions, suggesting a greater capacity to respond to climate change.
Researchers developed a method to deliver drugs across the blood-brain barrier using nasal mucosal grafting, showing neuroprotection in Parkinson's mouse models. The technique has potential to treat various brain disorders, including neurodegenerative diseases and psychiatric conditions.
Researchers at King's College London have identified a new gene, HIFalpha, that regulates nerve signals from damaged mitochondria in fruit flies. Switching off the HIFalpha gene restores nerve function and prevents early failure of nerve cells caused by mitochondrial damage.
A small phase I clinical trial found that an FDA-approved leukemia drug improved cognition, motor skills, and non-motor function in patients with Parkinson's disease and Lewy body dementia. The drug, nilotinib, also reduced toxic proteins linked to disease progression.
Researchers led by Assia Shisheva found a novel interaction partner of the ArPIKfyve-Sac3 complex in the brain, which binds Synphilin-1 and prevents its aggregation. This discovery may lead to new therapeutic approaches for reducing cytoplasmic aggregates in Parkinson's disease.
A new study found that people with Parkinson's disease psychosis who took antipsychotic medication were four times more likely to die than those who didn't. The treatment also led to serious health issues such as cognitive decline and worsening of Parkinson's symptoms.
A new study has found a potential treatment for Parkinson's disease by targeting specific nerve cells, showing promising results in rats. The technique could lead to less invasive and more precise treatment options for patients.
Scientists at UNC Eshelman School of Pharmacy created macrophages that deliver glial cell-derived neurotrophic factor (GDNF) and teach neurons to produce the protein. The treatment has shown promise in reversing Parkinson's disease progression and promoting neuron survival.
Researchers at Columbia University Irving Medical Center discovered that long-term use of L-DOPA leads to dyskinesia due to striatonigral neurons becoming less responsive to GABA. This suggests that modulating these neurons could prevent or delay dyskinesia.
Researchers found that external brain stimulation, specifically transcranial direct current stimulation (tDCS), can compensate for the loss of dopamine in people with Parkinson's disease by decreasing the effort the brain has to put into getting its motor neurons to fire. This correction improves some patients' motor symptoms.
Researchers at Massachusetts General Hospital found that urate stimulates astrocytes to activate an antioxidant pathway believed to have a role in several neurodegenerative disorders. A phase 3 trial of a urate-elevating drug, led by Dr. Michael Schwarzschild, is planned to enroll 270 patients with early-stage Parkinson's disease.
Researchers have identified a new type of prion causing Multiple System Atrophy (MSA), a neurodegenerative disorder with similarities to Parkinson's disease. The discovery raises concerns about treatments and research involving contact with brain tissue from MSA patients.
A new study published in Restorative Neurology and Neuroscience reports that repetitive transcranial magnetic stimulation can reduce gait freezing in Parkinson's patients. The treatment, involving high-frequency rTMS, improved motor skills and continued to show benefits even after the intervention was stopped.
Brain cells in Parkinson's disease are vulnerable due to high energy consumption, which can lead to exhaustion and cell death. This discovery may lead to new treatment strategies for reducing energy consumption or improving energy production in neurons.
Protein misfolding diseases are rising in incidence and seeing increasing financial and healthcare burden. Recent advances in understanding these disorders provide fresh ideas for their future therapy.
Researchers at Rockefeller University have identified two proteins, SATB1 and ZDHHC2, that appear to protect neurons from degeneration in Parkinson's disease. These proteins were found to be more abundant in dopamine-producing neurons in the substantia nigra pars compacta region, which is less affected by the disease.
Researchers discover UDCA, a decades-used liver treatment, may slow Parkinson's disease progression by rescuing damaged mitochondria. Studies confirm beneficial effects on nerve cells and genetic animal models of the condition.
Researchers found that low-dose lithium reduced involuntary motor movements in Parkinson's disease mice, boosting dopamine synthesis via inhibition of calpain-1. This study adds to evidence that low-doses of the psychotropic drug could benefit patients suffering from the incurable condition.
Researchers at Scripps Research Institute will explore therapeutic potential of proteins regulating human health and associated diseases like Parkinson's and arthritis.
A new study published in PLOS Medicine suggests that taking diabetes medication glitazones may lower the risk of developing Parkinson's disease by 28%. Researchers analyzed data from over 160,000 diabetes patients and found a significant association between glitazone use and reduced incidence of Parkinson's.
A pilot study in Parkinson's disease suggests that remote recruitment and conduct of research visits is feasible and well-received by participants. The study leverages direct-to-consumer genetic testing and telemedicine to diagnose and treat diseases, potentially increasing participation in clinical research and accelerating diagnosis.
Researchers found that activating Nurr1, a class of proteins in the brain, protects dopamine neurons and improves motor control. The study suggests that existing anti-malaria drugs could be repurposed to treat Parkinson's disease.
The UK Parkinson's Excellence Network is a multi-disciplinary effort bringing together patients, healthcare professionals, and social care experts to develop patient-centered care. The network aims to improve treatment and raise awareness of the need for better care, with a focus on education and service development.
A study found that compounds in New Zealand blackcurrants increased mental performance indicators such as accuracy and attention, while also reducing the activity of monoamine oxidase enzymes. This may lead to potential benefits for brain health and managing symptoms of disorders like Parkinson's disease and depression.
Researchers found that patients who had undergone vagotomy were protected against developing Parkinson's disease, with a risk halved after 20 years. The study suggests that Parkinson's disease begins in the gut and spreads via the vagus nerve to the brain.
Researchers at the University of Pittsburgh School of Medicine have developed a gene therapy that reduces production of brain protein α-synuclein, preventing Parkinson's disease progression in an animal study. The therapy targets mitochondria and α-synuclein interaction, showing promising results in protecting dopamine neurons.
Researchers discover that different shapes of alpha-synuclein aggregates cause distinct neurodegenerative diseases, including Parkinson's disease and Multiple System Atrophy. The study suggests new possibilities for treating brain diseases with a drug that counteracts aggregate development.
Researchers will investigate mTOR's role in brain function and regulation using various techniques. Understanding its function in the striatum could lead to new therapies for neurodegenerative diseases.
Scientists have identified a new neural circuit in the brain that tracks movement speed and delivers this information to spatial memory systems. This discovery has important implications for understanding movement-related symptoms associated with Parkinson's disease and improving spatial memory.
Researchers found that older adults' cycling speed improved while completing cognitive tasks without sacrificing cognitive performance. The study suggests combining physical activity with mental tasks may encourage more vigorous exercise.
Researchers have discovered a novel biomarker that tracks Parkinson's progression in the brain, providing a new tool for diagnosis and treatment. The study uses MRI-based diffusion imaging to measure changes in brain tissue fluid levels, which can inform treatment decisions and identify promising new therapies.
A large study found that people with depression were 3.2 times more likely to develop Parkinson's disease within a year after diagnosis. The link between depression and Parkinson's disease remained even when adjusting for other conditions related to depression.
A large study found that people with depression are more likely to develop Parkinson's disease, with a threefold increased risk within the first year. The link between depression and Parkinson's disease holds true even after adjusting for other related conditions.
The American Comparative Literature Association honored Lois Parkinson Zamora for her pioneering studies on hemispheric American studies and modern Latin American literature. Her work has been recognized nationally, with numerous publications and awards, including the John and Rebecca Moores Distinguished Professorship.
A team of neuroscientists found that misfolded a-synuclein can activate microglia, leading to chronic inflammation. They also identified specific receptors on microglial cells that respond to the protein and tested drugs to reduce inflammation.
Researchers have made significant progress in cell transplantation therapy, demonstrating improved outcomes for patients with complete spinal cord injury and potential treatments for Parkinson's disease. Studies also show that human pluripotent stem cells hold promise for treating the disease.
A recent study by Ludwig Institute for Cancer Research has made a significant breakthrough in understanding the molecular mechanisms behind Parkinson's disease. The researchers discovered that disruption of a developmental mechanism, Lmx1b, leads to the death of dopamine-producing neurons, resulting in the symptoms of PD.
A new approach has reversed Parkinson's-like symptoms in rats by delivering dopamine via biodegradable nanoparticles that crossed the blood-brain barrier without side effects. This breakthrough could lead to a new treatment for human patients.
Researchers found that serum glucocorticoid kinase 1 (SGK1) protects brain cells by blocking pathways involved in neurodegeneration and alleviating mitochondrial dysfunction. Increasing SGK1 levels offers a potential therapeutic approach for Parkinson's disease, as naturally occurring levels are not sufficient to promote cell survival.
Researchers discovered that deep-brain stimulation (DBS) reduces excessive synchronization of brain activity in the motor cortex, a region governing body movements. This reduction leads to improved symptoms and facilitated movement in patients with Parkinson's disease.
A new study by McGill University researchers found that a 12-week tango course improved balance and functional mobility in 40 Parkinson's patients, while also showing modest benefits in cognitive functions. The dance style's social interaction and physical activity may have therapeutic value for PD patients.
Researchers developed a new approach to identify reliable blood biomarkers for Parkinson's disease, which may lead to early diagnosis and targeted treatments. The study found RNA signatures that correlate with the disease-causing mutations in the LRRK2 gene.
Researchers have developed a safe and effective therapeutic strategy for Parkinson's disease using mitomycin-treated embryonic stem cells. The treatment showed significant improvements in motor function and survival rate in mice, with no tumor formation detected.
Researchers found that inflammatory cells from the bloodstream play a key role in neurodegeneration in Parkinson's disease. CD95L-bearing immune cells cause damage to neurons, and blocking this molecule can prevent neurodegeneration in mice. This suggests that early treatment with drugs targeting CD95L might mitigate Parkinson's symptoms.
Patients with Parkinson's disease experienced improved or eliminated preoperative pain after eight years following subthalamic nucleus deep brain stimulation. However, new musculoskeletal pain developed in 75% of patients during the follow-up period.
The Michael J. Fox Foundation is supporting research on a novel therapy for Parkinson's disease by Dr Bryce Vissel and Sandy Stayte at the Garvan Institute of Medical Research. The prototype drug targets kainate receptors to slow disease progression.
Scientists at OIST Graduate University found that cell groups in the neostriatum do not communicate with each other and are less interconnected. The discovery has implications for studying diseases like Parkinson's, which affects motor control.
New research confirms GDNF is not necessary for maintaining dopamine neurons, contradicting previous findings. The absence of GDNF in mice did not cause significant damage to the midbrain dopamine system or trigger motor disorders.
Researchers discovered a new pathway in the brain's striatum where several areas communicate to make spatial decisions, such as estimating where to swing a bat or finding a car. This knowledge may lead to improved treatments for Parkinson's disease by strengthening damaged pathways.
Scientists develop peptide that binds to misshapen α-synuclein protein, stopping toxic fibril formation and brain cell death. The research offers a potential new approach for slowing Parkinson's disease progression.
Researchers discovered a skin test that can detect abnormal proteins associated with Alzheimer's and Parkinson's diseases. The study used skin biopsies to compare patients' protein levels, revealing seven times higher tau protein levels for those with both conditions.
A UBC study shows that Twitter is a valuable resource for healthcare professionals, with 25% of tweets about spinal cord injury coming from medical experts. The study also found that users discussing Parkinson's disease were more likely to share new research tools and methods.
Researchers have discovered a novel mechanism of neuronal death involved in neurodegenerative protein-misfolding diseases like Alzheimer's and Parkinson's. The study found that the loss of NAD+ is the primary cause of neuronal demise, and restoring it can rescue neurons.
Researchers at Karolinska Institutet found that eltoprazine significantly reduced Parkinson's disease patients' dyskinesia while maintaining anti-Parkinsonian effects. The treatment was well-tolerated and shows promise as a new therapeutic principle for treating L-dopa-induced dyskinesia.
A recent study published in JAMA found that creatine monohydrate treatment did not improve clinical outcomes for patients with early and treated Parkinson disease. The study, which followed 1,741 participants for up to 8 years, suggests that creatine may not be a viable treatment option for slowing disease progression.
Global sea ice has been decreasing at an average annual rate of 13,500 square miles since 1979, with the Arctic losing more than it gains in Antarctica. The Arctic ice decrease has accelerated over time, leading to increased absorption of solar radiation and further heating.
Researchers at UT Southwestern Medical Center developed a wearable sensor system to track gait, balance, and other movements in individuals with Parkinson's disease. The APDM Mobility Lab can effectively assess the severity of the disorder even when medications are used to reduce symptoms.
A new study by University of Cambridge researchers identified a critical threshold in alpha-synuclein protein levels that increases the chances of aggregation and neurodegeneration. The findings provide a mechanistic description of the initial molecular events leading to Parkinson's disease.
Researchers found that xanthohumol, a compound in hops, can protect neuronal cells from oxidative damage, potentially slowing the development of brain disorders like Alzheimer's and Parkinson's diseases. The study suggests xanthohumol could be a promising candidate for fighting neurodegenerative conditions.